Benzinga | Nov 5, 2020 05:09PM EST

ADMA Biologics Q3 EPS $(0.19), Inline, Sales $10.28M Beat $9.96M Estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $10.28 million which beat the analyst consensus estimate of $9.96 million by 3.17 percent. This is a 42.27 percent increase over sales of $7.22 million the same period last year.